348 related articles for article (PubMed ID: 32233938)
1. Matrix Metalloproteinases and Glaucoma Treatment.
Weinreb RN; Robinson MR; Dibas M; Stamer WD
J Ocul Pharmacol Ther; 2020 May; 36(4):208-228. PubMed ID: 32233938
[TBL] [Abstract][Full Text] [Related]
2. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells.
Ooi YH; Oh DJ; Rhee DJ
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5259-65. PubMed ID: 19443729
[TBL] [Abstract][Full Text] [Related]
3. Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs.
Lee SS; Robinson MR; Weinreb RN
J Glaucoma; 2019 Sep; 28(9):846-857. PubMed ID: 31261285
[TBL] [Abstract][Full Text] [Related]
4. Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells.
Heo JY; Ooi YH; Rhee DJ
Exp Eye Res; 2020 May; 194():108019. PubMed ID: 32222455
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma.
Rönkkö S; Rekonen P; Kaarniranta K; Puustjärvi T; Teräsvirta M; Uusitalo H
Graefes Arch Clin Exp Ophthalmol; 2007 May; 245(5):697-704. PubMed ID: 17028863
[TBL] [Abstract][Full Text] [Related]
6. Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.
Yamada H; Yoneda M; Gosho M; Kato T; Zako M
BMC Ophthalmol; 2016 Mar; 16():26. PubMed ID: 26956170
[TBL] [Abstract][Full Text] [Related]
7. Pressure-induced expression changes in segmental flow regions of the human trabecular meshwork.
Vranka JA; Acott TS
Exp Eye Res; 2017 May; 158():67-72. PubMed ID: 27334250
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Prostaglandin Analogues on the Ciliary Zonular Fibers of the Rabbit Crystalline Lens.
Hwang HB; Kim SY
Curr Eye Res; 2018 Nov; 43(11):1357-1361. PubMed ID: 30015523
[TBL] [Abstract][Full Text] [Related]
9. Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.
Seal JR; Robinson MR; Burke J; Bejanian M; Coote M; Attar M
J Ocul Pharmacol Ther; 2019; 35(1):50-57. PubMed ID: 30335560
[TBL] [Abstract][Full Text] [Related]
10. TIMP1, TIMP2, and TIMP4 are increased in aqueous humor from primary open angle glaucoma patients.
Ashworth Briggs EL; Toh T; Eri R; Hewitt AW; Cook AL
Mol Vis; 2015; 21():1162-72. PubMed ID: 26539028
[TBL] [Abstract][Full Text] [Related]
11. Association between topical prostaglandin analog use and development of choroidal neovascular membranes in patients with concurrent glaucoma and age-related macular degeneration.
Scherer WJ
J Ocul Pharmacol Ther; 2006 Apr; 22(2):139-44. PubMed ID: 16722800
[TBL] [Abstract][Full Text] [Related]
12. Cellular basis for bimatoprost effects on human conventional outflow.
Stamer WD; Piwnica D; Jolas T; Carling RW; Cornell CL; Fliri H; Martos J; Pettit SN; Wang JW; Woodward DF
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5176-81. PubMed ID: 20435598
[TBL] [Abstract][Full Text] [Related]
13. Effects of antiglaucoma drops on MMP and TIMP balance in conjunctival and subconjunctival tissue.
Ito T; Ohguro H; Mamiya K; Ohguro I; Nakazawa M
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):823-30. PubMed ID: 16505013
[TBL] [Abstract][Full Text] [Related]
14. Deconstructing aqueous humor outflow - The last 50 years.
Kaufman PL
Exp Eye Res; 2020 Aug; 197():108105. PubMed ID: 32590004
[TBL] [Abstract][Full Text] [Related]
15. Effects of prostaglandins on the aqueous humor outflow pathways.
Weinreb RN; Toris CB; Gabelt BT; Lindsey JD; Kaufman PL
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S53-64. PubMed ID: 12204701
[TBL] [Abstract][Full Text] [Related]
16. Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway.
O'Callaghan J; Cassidy PS; Humphries P
Expert Opin Ther Targets; 2017 Nov; 21(11):1037-1050. PubMed ID: 28952395
[TBL] [Abstract][Full Text] [Related]
17. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells.
Oh DJ; Martin JL; Williams AJ; Russell P; Birk DE; Rhee DJ
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3887-95. PubMed ID: 16936101
[TBL] [Abstract][Full Text] [Related]
18. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
Craven ER; Walters T; Christie WC; Day DG; Lewis RA; Goodkin ML; Chen M; Wangsadipura V; Robinson MR; Bejanian M;
Drugs; 2020 Feb; 80(2):167-179. PubMed ID: 31884564
[TBL] [Abstract][Full Text] [Related]
19. Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.
Lee SS; Dibas M; Almazan A; Robinson MR
J Ocul Pharmacol Ther; 2019 Apr; 35(3):138-144. PubMed ID: 30698494
[TBL] [Abstract][Full Text] [Related]
20. Advances in glaucoma diagnosis and therapy for the next millennium: new drugs for trabecular and uveoscleral outflow.
Kaufman PL; Gabelt B; Tian B; Liu X
Semin Ophthalmol; 1999 Sep; 14(3):130-43. PubMed ID: 10790577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
